Top

Published in:

Open Access 08-03-2022 | Primary Immunodeficiency | Original Article

Progressive Depletion of B and T Lymphocytes in Patients with Ataxia Telangiectasia: Results of the Italian Primary Immunodeficiency Network

Authors: Emilia Cirillo, Agata Polizzi, Annarosa Soresina, Rosaria Prencipe, Giuliana Giardino, Caterina Cancrini, Andrea Finocchi, Beatrice Rivalta, Rosa M. Dellepiane, Lucia A. Baselli, Davide Montin, Antonino Trizzino, Rita Consolini, Chiara Azzari, Silvia Ricci, Lorenzo Lodi, Isabella Quinti, Cinzia Milito, Lucia Leonardi, Marzia Duse, Maria Carrabba, Giovanna Fabio, Patrizia Bertolini, Paola Coccia, Irene D’Alba, Andrea Pession, Francesca Conti, Marco Zecca, Claudio Lunardi, Manuela Lo Bianco, Santiago Presti, Laura Sciuto, Roberto Micheli, Dario Bruzzese, Vassilios Lougaris, Raffaele Badolato, Alessandro Plebani, Luciana Chessa, Claudio Pignata

Published in: Journal of Clinical Immunology | Issue 4/2022

Abstract

Ataxia telangiectasia (AT) is a rare neurodegenerative genetic disorder due to bi-allelic mutations in the Ataxia Telangiectasia Mutated (ATM) gene. The aim of this paper is to better define the immunological profile over time, the clinical immune-related manifestations at diagnosis and during follow-up, and to attempt a genotype–phenotype correlation of an Italian cohort of AT patients. Retrospective data of 69 AT patients diagnosed between December 1984 and November 2019 were collected from the database of the Italian Primary Immunodeficiency Network. Patients were classified at diagnosis as lymphopenic (Group A) or non-lymphopenic (Group B). Fifty eight out of 69 AT patients (84%) were genetically characterized and distinguished according to the type of mutations in truncating/truncating (TT; 27 patients), non-truncating (NT)/T (28 patients), and NT/NT (5 patients). In 3 patients, only one mutation was detected. Data on age at onset and at diagnosis, cellular and humoral compartment at diagnosis and follow-up, infectious diseases, signs of immune dysregulation, cancer, and survival were analyzed and compared to the genotype. Lymphopenia at diagnosis was related per se to earlier age at onset. Progressive reduction of cellular compartment occurred during the follow-up with a gradual reduction of T and B cell number. Most patients of Group A carried bi-allelic truncating mutations, had a more severe B cell lymphopenia, and a reduced life expectancy. A trend to higher frequency of interstitial lung disease, immune dysregulation, and malignancy was noted in Group B patients. Lymphopenia at the onset and the T/T genotype are associated with a worst clinical course. Several mechanisms may underlie the premature and progressive immune decline in AT subjects.

Available only for authorised users

Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11(1):159. https://doi.org/10.1186/s13023-016-0543-7.CrossRefPubMedPubMedCentral

Amirifar P, Ranjouri MR, Yazdani R, Abolhassani H, Aghamohammadi A. Ataxia-telangiectasia: a review of clinical features and molecular pathology. Pediatr Allergy Immunol. 2019;30(3):277–88. https://doi.org/10.1111/pai.13020.CrossRefPubMed

Rotman G, Shiloh Y. ATM: from gene to function. Hum Mol Genet. 1998;7(10):1555–63. https://doi.org/10.1093/hmg/7.10.1555.CrossRefPubMed

Chessa L, Piane M, Magliozzi M, Torrente I, Savio C, Lulli P, et al. Founder effects for ATM gene mutations in Italian ataxia telangiectasia families. Ann Hum Genet. 2009;73(Pt 5):532–9. https://doi.org/10.1111/j.1469-1809.2009.00535.x.CrossRefPubMed

Driessen GJ, Ijspeert H, Weemaes CM, Haraldsson Á, Trip M, Warris A, et al. Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. J Allergy Clin Immunol. 2013;131(5):1367-75.e9. https://doi.org/10.1016/j.jaci.2013.01.053.CrossRefPubMed

Guleria A, Chandna S. ATM kinase: Much more than a DNA damage responsive protein. DNA Repair (Amst). 2016;39:1–20. https://doi.org/10.1016/j.dnarep.2015.12.009.CrossRef

Levy A, Lang AE. Ataxia-telangiectasia: a review of movement disorders, clinical features, and genotype correlations. Mov Disord. 2018;33(8):1238–47. https://doi.org/10.1002/mds.27319.CrossRefPubMed

Reina-San-Martin B, Chen HT, Nussenzweig A, Nussenzweig MC. ATM is required for efficient recombination between immunoglobulin switch regions. J Exp Med. 2004;200(9):1103–10. https://doi.org/10.1084/jem.20041162.CrossRefPubMedPubMedCentral

Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst). 2004;3(8–9):1187–96. https://doi.org/10.1016/j.dnarep.2004.04.010.CrossRef

10.

Jackson TJ, Chow G, Suri M, Byrd P, Taylor MR, Whitehouse WP. Longitudinal analysis of the neurological features of ataxia-telangiectasia. Dev Med Child Neurol. 2016;58(7):690–7. https://doi.org/10.1111/dmcn.13052.CrossRefPubMed

11.

Cirillo E, Del Giudice E, Micheli R, Cappellari AM, Soresina A, Dellepiane RM, et al. Minimum effective betamethasone dosage on the neurological phenotype in patients with ataxia-telangiectasia: a multicenter observer-blind study. Eur J Neurol. 2018;25(6):833–40. https://doi.org/10.1111/ene.13606.CrossRefPubMed

12.

Prencipe R, Cirillo E, Giardino G, Gallo V, Menotta M, Magnani M, et al. In ataxia-telangiectasia, oral betamethasone administration ameliorates lymphocytes functionality through modulation of the IL-7/IL-7Rα axis paralleling the neurological behavior: a comparative report of two cases. Immunol Invest. 2021;50(2–3):295–303. https://doi.org/10.1080/08820139.2020.1761379.CrossRefPubMed

13.

Notarangelo L, Casanova JL, Fischer A, Puck J, Rosen F, Seger R, et al. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol. 2004;114(3):677–87. https://doi.org/10.1016/j.jaci.2004.06.044.CrossRefPubMed

14.

Picard C, Bobby Gaspar H, Al-Herz W, Bousfiha A, Casanova JL, Chatila T, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96–128. https://doi.org/10.1007/s10875-017-0464-9.CrossRefPubMed

15.

Abinun M, Albert M, Beaussant Cohen S, Buckland M, Bustamante J, Cant A, et al. ESID Registry — working definitions for clinical diagnosis of IEI. 2019:1–205.

16.

Schatorjé EJ, Gemen EF, Driessen GJ, Leuvenink J, van Hout RW, de Vries E. Paediatric reference values for the peripheral T cell compartment. Scand J Immunol. 2012;75(4):436–44. https://doi.org/10.1111/j.1365-3083.2012.02671.x.CrossRefPubMed

17.

Yel L. Selective IgA deficiency. J Clin Immunol. 2010;30(1):10–6. https://doi.org/10.1007/s10875-009-9357-x.CrossRefPubMedPubMedCentral

18.

Schroeder SA, Zielen S. Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2014;49(4):389–99. https://doi.org/10.1002/ppul.22817.CrossRefPubMed

19.

van Os NJH, Haaxma CA, van der Flier M, Merkus P, van Deuren M, de Groot IJM, et al. Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Dev Med Child Neurol. 2017;59(7):680–9. https://doi.org/10.1111/dmcn.13424.CrossRefPubMed

20.

Russo I, Cosentino C, Del Giudice E, Broccoletti T, Amorosi S, Cirillo E, et al. In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol. 2009;16(6):755–9. https://doi.org/10.1111/j.1468-1331.2009.02600.x.CrossRefPubMed

21.

Zannolli R, Buoni S, Betti G, Salvucci S, Plebani A, Soresina A, et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord. 2012;27(10):1312–6. https://doi.org/10.1002/mds.25126.CrossRefPubMed

22.

Chessa L, Leuzzi V, Plebani A, Soresina A, Micheli R, D’Agnano D, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis. 2014;9:5. https://doi.org/10.1186/1750-1172-9-5.CrossRefPubMedPubMedCentral

23.

Leuzzi V, Micheli R, D’Agnano D, Molinaro A, Venturi T, Plebani A, et al. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e98. https://doi.org/10.1212/nxi.0000000000000098.CrossRefPubMedPubMedCentral

24.

Schon K, van Os NJH, Oscroft N, Baxendale H, Scoffings D, Ray J, et al. Genotype, extrapyramidal features, and severity of variant ataxia-telangiectasia. Ann Neurol. 2019;85(2):170–80. https://doi.org/10.1002/ana.25394.CrossRefPubMedPubMedCentral

25.

van Os NJH, Chessa L, Weemaes CMR, van Deuren M, Fiévet A, van Gaalen J, et al. Genotype-phenotype correlations in ataxia telangiectasia patients with ATM c.3576G>A and c.8147T>C mutations. J Med Genet. 2019;56(5):308–16. https://doi.org/10.1136/jmedgenet-2018-105635.CrossRefPubMed

26.

Mandola AB, Reid B, Sirror R, Brager R, Dent P, Chakroborty P, et al. Ataxia telangiectasia diagnosed on newborn screening-case cohort of 5 years’ experience. Front Immunol. 2019;10:2940. https://doi.org/10.3389/fimmu.2019.02940.CrossRefPubMedPubMedCentral

27.

Dasouki M, Jabr A, AlDakheel G, Elbadaoui F, Alazami AM, Al-Saud B, et al. TREC and KREC profiling as a representative of thymus and bone marrow output in patients with various inborn errors of immunity. Clin Exp Immunol. 2020;202(1):60–71. https://doi.org/10.1111/cei.13484.CrossRefPubMedPubMedCentral

28.

Speckmann C, Doerken S, Aiuti A, Albert MH, Al-Herz W, Allende LM, et al. A prospective study on the natural history of patients with profound combined immunodeficiency: an interim analysis. J Allergy Clin Immunol. 2017;139(4):1302-10.e4. https://doi.org/10.1016/j.jaci.2016.07.040.CrossRefPubMed

29.

Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. J Allergy Clin Immunol. 2018;141(4):1450–8. https://doi.org/10.1016/j.jaci.2017.06.049.CrossRefPubMed

30.

Krauthammer A, Lahad A, Goldberg L, Sarouk I, Weiss B, Somech R, et al. Elevated IgM levels as a marker for a unique phenotype in patients with ataxia telangiectasia. BMC Pediatr. 2018;18(1):185. https://doi.org/10.1186/s12887-018-1156-1.CrossRefPubMedPubMedCentral

31.

Moeini Shad T, Yousefi B, Amirifar P, Delavari S, Rae W, Kokhaei P, et al. Variable abnormalities in T and B cell subsets in ataxia telangiectasia. J Clin Immunol. 2021;41(1):76–88. https://doi.org/10.1007/s10875-020-00881-9.CrossRefPubMed

32.

D’Assante R, Fusco A, Palamaro L, Polishchuk E, Polishchuk R, Bianchino G, et al. Abnormal cell-clearance and accumulation of autophagic vesicles in lymphocytes from patients affected with ataxia-teleangiectasia. Clin Immunol. 2017;175:16–25. https://doi.org/10.1016/j.clim.2016.11.015.CrossRefPubMed

33.

Shiloh Y, Lederman HM. Ataxia-telangiectasia (A-T): an emerging dimension of premature ageing. Ageing Res Rev. 2017;33:76–88. https://doi.org/10.1016/j.arr.2016.05.002.CrossRefPubMed

34.

McGrath-Morrow SA, Ndeh R, Helmin KA, Khuder B, Rothblum-Oviatt C, Collaco JM, et al. DNA methylation and gene expression signatures are associated with ataxia-telangiectasia phenotype. Sci Rep. 2020;10(1):7479. https://doi.org/10.1038/s41598-020-64514-2.CrossRefPubMedPubMedCentral

35.

Stagni V, Ferri A, Cirotti C, Barilà D. ATM kinase-dependent regulation of autophagy: a key player in senescence? Front Cell Dev Biol. 2020;8:599048. https://doi.org/10.3389/fcell.2020.599048.CrossRefPubMed

36.

van Os NJH, Jansen AFM, van Deuren M, Haraldsson A, van Driel NTM, Etzioni A, et al. Ataxia-telangiectasia: immunodeficiency and survival. Clin Immunol. 2017;178:45–55. https://doi.org/10.1016/j.clim.2017.01.009.CrossRefPubMed

37.

Chiappini E, Santamaria F, Marseglia GL, Marchisio P, Galli L, Cutrera R, et al. Prevention of recurrent respiratory infections: inter-society consensus. Ital J Pediatr. 2021;47(1):211. https://doi.org/10.1186/s13052-021-01150-0.CrossRefPubMedPubMedCentral

38.

de Benedictis FM, Bush A. Recurrent lower respiratory tract infections in children. BMJ. 2018;362:k2698. https://doi.org/10.1136/bmj.k2698.CrossRefPubMed

39.

Garcia B, Flume PA. Pulmonary complications of cystic fibrosis. Semin Respir Crit Care Med. 2019;40(6):804–9. https://doi.org/10.1055/s-0039-1697639.CrossRefPubMed

40.

Boone PM, Scott RM, Marciniak SJ, Henske EP, Raby BA. The genetics of pneumothorax. Am J Respir Crit Care Med. 2019;199(11):1344–57. https://doi.org/10.1164/rccm.201807-1212CI.CrossRefPubMedPubMedCentral

41.

Patrawala M, Cui Y, Peng L, Fuleihan RL, Garabedian EK, Patel K, et al. Pulmonary disease burden in primary immune deficiency disorders: data from USIDNET registry. J Clin Immunol. 2020;40(2):340–9. https://doi.org/10.1007/s10875-019-00738-w.CrossRefPubMed

42.

Jiang YN, Ni XY, Yan HQ, Shi L, Lu NN, Wang YN, et al. Interleukin 6-triggered ataxia-telangiectasia mutated kinase activation facilitates epithelial-to-mesenchymal transition in lung cancer by upregulating vimentin expression. Exp Cell Res. 2019;381(2):165–71. https://doi.org/10.1016/j.yexcr.2019.05.011.CrossRefPubMed

43.

Duecker R, Baer P, Eickmeier O, Strecker M, Kurz J, Schaible A, et al. Oxidative stress-driven pulmonary inflammation and fibrosis in a mouse model of human ataxia-telangiectasia. Redox Biol. 2018;14:645–55. https://doi.org/10.1016/j.redox.2017.11.006.CrossRefPubMed

44.

Schroeder SA, Swift M, Sandoval C, Langston C. Interstitial lung disease in patients with ataxia-telangiectasia. Pediatr Pulmonol. 2005;39(6):537–43. https://doi.org/10.1002/ppul.20209.CrossRefPubMed

45.

Bhatt JM, Bush A, van Gerven M, Nissenkorn A, Renke M, Yarlett L, et al. ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. Eur Respir Rev. 2015;24(138):565–81. https://doi.org/10.1183/16000617.0066-2015.CrossRefPubMed

46.

Duvvuri B, Duvvuri VR, Grigull J, Martin A, Pan-Hammarström Q, Wu GE, et al. Altered spectrum of somatic hypermutation in common variable immunodeficiency disease characteristic of defective repair of mutations. Immunogenetics. 2011;63(1):1–11. https://doi.org/10.1007/s00251-010-0483-7.CrossRefPubMed

47.

Cinetto F, Scarpa R, Pulvirenti F, Quinti I, Agostini C, Milito C. Appropriate lung management in patients with primary antibody deficiencies. Expert Rev Respir Med. 2019;13(9):823–38. https://doi.org/10.1080/17476348.2019.1641085.CrossRefPubMed

48.

Dhalla F, Lochlainn DJM, Chapel H, Patel SY. Histology of interstitial lung disease in common variable immune deficiency. Front Immunol. 2020;11:605187. https://doi.org/10.3389/fimmu.2020.605187.CrossRefPubMedPubMedCentral

49.

van de Ven A, Alfaro TM, Robinson A, Baumann U, Bergeron A, Burns SO, et al. Managing granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency disorders: e-GLILDnet international clinicians survey. Front Immunol. 2020;11:606333. https://doi.org/10.3389/fimmu.2020.606333.CrossRefPubMedPubMedCentral

50.

McGrath-Morrow SA, Collaco JM, Detrick B, Lederman HM. Serum interleukin-6 levels and pulmonary function in ataxia-telangiectasia. J Pediatr. 2016;171:256-61.e1. https://doi.org/10.1016/j.jpeds.2016.01.002.CrossRefPubMedPubMedCentral

51.

McGrath-Morrow SA, Ndeh R, Collaco JM, Rothblum-Oviatt C, Wright J, O’Reilly MA, et al. Inflammation and transcriptional responses of peripheral blood mononuclear cells in classic ataxia telangiectasia. PLoS ONE. 2018;13(12):e0209496. https://doi.org/10.1371/journal.pone.0209496.CrossRefPubMedPubMedCentral

52.

Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol. 2008;28(Suppl 1):S62–6. https://doi.org/10.1007/s10875-008-9171-x.CrossRefPubMed

53.

Zaki-Dizaji M, Akrami SM, Azizi G, Abolhassani H, Aghamohammadi A. Inflammation, a significant player of ataxia-telangiectasia pathogenesis? Inflamm Res. 2018;67(7):559–70. https://doi.org/10.1007/s00011-018-1142-y.CrossRefPubMed

54.

Soresina A, Meini A, Lougaris V, Cattaneo G, Pellegrino S, Piane M, et al. Different clinical and immunological presentation of ataxia-telangiectasia within the same family. Neuropediatrics. 2008;39(1):43–5. https://doi.org/10.1055/s-2008-1076736.CrossRefPubMed

55.

Bender CF, Sikes ML, Sullivan R, Huye LE, Le Beau MM, Roth DB, et al. Cancer predisposition and hematopoietic failure in Rad50(S/S) mice. Genes Dev. 2002;16(17):2237–51. https://doi.org/10.1101/gad.1007902.CrossRefPubMedPubMedCentral

56.

Alterman N, Fattal-Valevski A, Moyal L, Crawford TO, Lederman HM, Ziv Y, et al. Ataxia-telangiectasia: mild neurological presentation despite null ATM mutation and severe cellular phenotype. Am J Med Genet A. 2007;143a(16):1827–34. https://doi.org/10.1002/ajmg.a.31853.CrossRefPubMed

57.

d’Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer. 2008;8(7):512–22. https://doi.org/10.1038/nrc2440.CrossRefPubMed

Title: Progressive Depletion of B and T Lymphocytes in Patients with Ataxia Telangiectasia: Results of the Italian Primary Immunodeficiency Network
Authors: Emilia Cirillo
Agata Polizzi
Annarosa Soresina
Rosaria Prencipe
Giuliana Giardino
Caterina Cancrini
Andrea Finocchi
Beatrice Rivalta
Rosa M. Dellepiane
Lucia A. Baselli
Davide Montin
Antonino Trizzino
Rita Consolini
Chiara Azzari
Silvia Ricci
Lorenzo Lodi
Isabella Quinti
Cinzia Milito
Lucia Leonardi
Marzia Duse
Maria Carrabba
Giovanna Fabio
Patrizia Bertolini
Paola Coccia
Irene D’Alba
Andrea Pession
Francesca Conti
Marco Zecca
Claudio Lunardi
Manuela Lo Bianco
Santiago Presti
Laura Sciuto
Roberto Micheli
Dario Bruzzese
Vassilios Lougaris
Raffaele Badolato
Alessandro Plebani
Luciana Chessa
Claudio Pignata
Publication date: 08-03-2022
Publisher: Springer US
Keywords: Primary Immunodeficiency
Ataxia Telangiectasia
Lymphopenia
Published in: Journal of Clinical Immunology / Issue 4/2022
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-022-01234-4

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2022

Early Onset of TNFα-Driven Arthritis, Auto-inflammation, and Progressive Loss of Vision in a Patient with ALPK1 Mutation

COVID-19 Vaccine Uptake and Efficacy in a National Immunodeficiency Cohort

TCRαβ-Depleted Haploidentical Grafts Are a Safe Alternative to HLA-Matched Unrelated Donor Stem Cell Transplants for Infants with Severe Combined Immunodeficiency

A Novel Kindred with MyD88 Deficiency

Lung MRI- Changing Paradigms in Evaluation of Chronic Granulomatous Disease in Children

X-Linked Agammaglobulinemia: Infection Frequency and Infection-Related Mortality in the USIDNET Registry

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage